• KOL
    • Aortic Valve
    • Jean C Fajadet
    • Jean C Fajadet: Influence Statistics

      Jean C Fajadet

      Jean C Fajadet

      Show email address

      Clinique Pasteur, Toulouse, France | Clinique Pasteur, Toulouse, France. | Clinique Pasteur, 31000 Toulouse, France;, fajadet@interv-cardio-toul.com | Département de ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jean C Fajadet:Expert Impact

      Concepts for whichJean C Fajadethas direct influence:Aortic valve,Coronary artery,Myocardial infarction,Coronary stenting,Diabetic patients,European association,Coronary angioplasty,Coronary stents.

      Jean C Fajadet:KOL impact

      Concepts related to the work of other authors for whichfor which Jean C Fajadet has influence:Aortic valve,Coronary artery,Myocardial infarction,Eluting stents,Stent thrombosis,Balloon angioplasty.

      KOL Resume for Jean C Fajadet

      Year
      2022

      Clinique Pasteur, Toulouse, France

      2021

      Clinique Pasteur, 31000 Toulouse, France;,

      2020

      Département de Cardiologie, Clinique Pasteur, Toulouse, France

      2019

      Clinique Pasteur, Toulouse, France (J.F.).

      2017

      Stanford University, Stanford, CA, USA

      Clinique Pasteur Department of Cardiology Toulouse France

      2016

      Department of Cardiology, Pasteur Hospital, Toulouse, France

      2015

      Cardiology Department, Clinique Pasteur, Toulouse, France

      Cardiovascular Research Center Aalst , OLV Hospital , Moorselbaan 164, Aalst 9300 , Belgium

      2014

      From the Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France (N.D., E.P.); INSERM U 970, Paris, France (N.D., E.P.); Université Paris Descartes, Paris, France (N.D., E.P.); Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France (P.G.S.); INSERM U 698, Paris, France (P.G.S.); Université Paris Diderot, Paris, France (P.G.S.); Centre Hospitalier Régional Universitaire de Lille, Lille, France (P.G.); Hôpital Jean Minjoz, Besançon, France (F.S.); Université de Franche Comté, Besançon, France (F.S.); Centre Hospitalier d’Annecy, Annecy, France (L.B.); Hôpital du Bocage, Dijon, France (Y.C.); Université de Bourgogne, Dijon, France (Y.C.); Clinique Pasteur, Toulouse, France (J. Fajadet); Centre Hospitalier Régional de Metz-Thionville, Metz, France (K.K.); Hôpital du Haut Levêque, Pessac, France (P.C.); Université Bordeaux Segalen, Bordeaux, France (P.C.); Hôpital Rangueil, Toulouse, France (J. Ferrières); INSERM U1027, Toulouse, France (J. Ferrières); Université Paul Sabatier Toulouse, Toulouse, France (J. Ferrières); Assistance Publique-Hôpitaux de Paris, Hôpital St Antoine, Unité de Recherche Clinique (URCEST), Paris, France (T.S.); INSERM U698, Paris, France (T.S.); and Université Pierre et Marie Curie, Paris, France (T.S.).

      2013

      Interventional Cardiology Unit, Clinique Pasteur, Toulouse, France

      2012

      Department of Cardiology, La Clinique Pasteur, Toulouse, France

      2010

      Clinique Pasteur, 45 avenue de Lombez, Toulouse, France.

      2006

      From the Clinique Pasteur, Toulouse, France (J.F.); Cardiovascular Center, Aalst, Belgium (W.W.); OLV Gasthuis, Amsterdam, the Netherlands (G.-J.L.); Krankenhaus Sankt Georg, Hamburg, Germany (K.-H.K.); Mercy Hospital, Auckland, New Zealand (J.O.); Universitätsklinikum, Hamburg-Eppendorf, Germany (T.M.); Brigham and Women’s Hospital, Boston, Mass (J.J.P); Stanford University, Stanford, Calif (P.F); Medtronic Vascular, Santa Rosa, Calif (R.B.); and Harvard Medical School, Boston, Mass (R.E.K).

      2005

      From the Clinique Pasteur, Toulouse, France (F.J.); Institut Cardiovasculaire Paris Sud, Massy, France (M.-C.M.); Albert-Ludwigs-Universitätskliniken, Kardiologie, Freiburg, Germany (C.B.); Clinique Beauregard, Marseille, France (P.B.); Thoraxcentrum, Rotterdam, the Netherlands (P.W.S.); Onze Lieve Vrouw Ziekenhuis, Cardiologie Intervasculair, Aalst, Belgium (W.W.); Clinica Cardiológyca C. Constantini, Curitiba, Paraná, Brazil (C.R.C.); Hôpital Broussais, Paris, France (J.-L.G.); Centre...

      2004

      Unité de Cardiologie Interventionnelle, Clinique Pasteur — 45 avenue de Lombez — 31075, Toulouse

      2003

      Unite De Cardiologie Interventionnelle, Clinique Pasteur, Toulouse, France

      2002

      From Clinique Pasteur (J.M., B.F., M.B., I.M.B., B.C., J.F.), Centre de Cardiologie Interventionelle, Toulouse, France; Experimental Surgery and Transplantation Institute, Ospedale Maggiore IRCCS, University of Milano (L.G., M.C., A.G.); Centro Cuore Columbus (L.G., C.D.M., R.A.), Milano; Clinical Physiology Institute (C.P., M.K.), University of Pisa, Italy; and Institut für Pathophysiologie (G.H.), Universitätsklinikum, Essen, Germany.

      Clinique Pasteur, Toulouse, France (J.F.)

      2001

      Department of Cardiology, The Geelong Hospital, Geelong, Victoria, Australia

      Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

      Unité de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France

      2000

      Interventionnal Cardiology Unit, Clinique Pasteur, Toulouse, France

      1999

      From the Tel Aviv Sourasky Medical Center (U.R., S.L., H.I.M.), Tel Aviv, Israel; Hanusch KH (G. Gaul), Vienna, Austria; Universitatsklinikum Essen (R.E.), Essen, Germany; Universitaatsspital Zurich (F.A.), Zurich, Switzerland; Medellin Clinic (D.V.), Medellin, Colombia; Herzzentrum Frankfurt (H.S.), Frankfurt, Germany; Uni Kiel (R.S.), Kiel, Germany; Shaio Clinic (G. Gomez), Bogata, Colombia; Stadt Klinikum Oldenburg (J.T.), Oldenburg, Germany; Centro Cardiologico Milan (A.B.), Milan, Italy;...

      1998

      Clinique Pasteur, Centre de Cardiologie Interventionelle, Toulouse, France;

      1997

      Clinique Pasteur, Unité de Caridiologie Interventionelle, Toulouse, France.

      Clinica Medica Generale, Centro Fisiologia Clinica, Università di Milano, IRCCS Ospedale Maggiore, Milan, Italy

      1996

      From the Thoraxcenter, Department of Interventional Cardiology, Erasmus University, Rotterdam, Netherlands.

      1995

      Division of Cardiology, Sahlgrenska Hospital, Gåteborg, Sweden

      Clinique Pastaur, Toulouse, France

      Sequoia Hospital and the Pacific Foundation for Cardiovascular Research, Redwood City, CA

      Thoraxcenter, Erasmus Univ. Rotterdam, The Netherlands

      1994

      Clinica Medica Generale, Università di Milano, Italy.

      1992

      Clinique Pasteur and Dakota Medical Center, University of North Dakota School of Medicine, Fargo, North Dakota; and Unité de Cardiologie Interventionnelle, Clinique Pasteur, Toulouse, France

      1990

      Centre Cardiologique du Nord, Saint‐Denis, and Clinique Pasteur, Toulouse, France

      1988

      University Hospital Toulouse Purpan, Department of Hemodynamics, France

      1987

      University Hospital Purpan Toulouse, Department of Hemodynamics, Toulouse, France

      1985

      Hopital Purpan, Centre Hospitalier Regional De Toulouse, Service De Cardiologie, Place Du Docteur Baylac, Toulouse, France

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jean C Fajadet is among the top experts in the world.
      Concept World rank
      myocardial infarction 05 #1
      subsequent tlr rates #1
      55 95ci #1
      clinical outcome multivessel #1
      stent subacute thrombosis #1
      ulmca mace #1
      repeat revascularizations #1
      98 hospitalisation #1
      bipax clinical #1
      pax dedicated #1
      levels angioplasty #1
      kidney norepinephrine levels #1
      bipax #1
      balloon angioplasty diabetics #1
      angioplasty stable patients #1
      cooling arterial #1
      stent clinically #1
      endoluminal reconstruction svgs #1
      intracoronary doses nitrates #1
      study disrupt #1
      minvasys sas #1
      balloon preserves #1
      severe lmca stenosis #1
      cardiologists europe #1
      noninsulinrequiring #1
      adrenergic coronary atherectomy #1
      4 singleuse radiofrequency #1
      accelerated neoatherosclerosis #1
      adrenergic elastic recoil #1
      lesion length pv #1
      corevalve accutrak aims #1
      surgical risk stenting #1
      esc database #1
      diffusely degenerated #1
      coronary stenting diabetics #1
      catheterbased ultrasound energy #1
      balloon demonstrated #1
      restenosis disease progression #1
      postprocedural asymmetry #1
      distal lesion 95ci #1
      revascularizations follow #1
      fellowship training position #1
      10 normotensive pigs #1
      arterial medial layer #1
      diabetics balloon angioplasty #1
      126 115 #1
      radiofrequency iberis #1
      years svgs #1
      implantation shortening #1
      september 39 patients #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Jean C Fajadet

      KOL-Index: 17503

      OBJECTIVES: The aim of this study was to assess the long-term safety and efficacy of the CYPHER (Cordis, Johnson and Johnson, Bridgewater, New Jersey) sirolimus-eluting coronary stent (SES) in percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

      BACKGROUND: Concern over the safety of drug-eluting stents implanted during PCI for STEMI remains, and long-term follow-up from randomized trials are necessary. TYPHOON (Trial to assess the use of the ...

      Known for Myocardial Infarction | Balloon Angioplasty | Ses Bms | Eluting Coronary | Sirolimus Stents
      KOL-Index: 16465

      BACKGROUND: Vasoconstriction occurs after percutaneous transluminal coronary angioplasty (PTCA) along the dilated vessel. The vasomotor changes, initiated by the mechanical stretch of the stenotic region, are thought to be due to various mechanisms but whether the sympathetic nervous system plays a role in this phenomenon remains unknown.

      METHODS AND RESULTS: Quantitative angiography (ARTREK) was performed in 45 patients undergoing an epicardial vessel PTCA for a stenosis of 76 +/- 1% ...

      Known for Coronary Vasoconstriction | Distal Segment | Adrenergic Alpha Receptors | Percutaneous Transluminal | Ptca Stenosis
      KOL-Index: 15929

      OBJECTIVES: The aim of this study was to compare outcomes after transfemoral transcatheter aortic valve implantation with the Medtronic CoreValve (MCV) versus the Edwards SAPIEN/SAPIEN XT transcatheter heart valve (ESV) for severe aortic stenosis.

      BACKGROUND: No large matched comparison study has been conducted so far evaluating both commercially available devices.

      METHODS: The data from databases of 4 experienced European centers were pooled and analyzed. Due to differences in baseline ...

      Known for Mcv Esv | Valve Implantation | Edwards Sapien | Transcatheter Aortic | 1 Year
      KOL-Index: 15297

      OBJECTIVES: This study sought to compare the safety and efficacy of 2 dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) (Boston Scientific Corp., Natick, Massachusetts) compared with the durable polymer PROMUS Element EES (Boston Scientific Corp.).

      BACKGROUND: Durable polymer coatings on drug-eluting stents have been associated with chronic inflammation and impaired healing. Bioabsorbable polymer-coated drug-delivery systems may reduce the risk of ...

      Known for Coronary Stent | Primary Endpoint | Evolve Trial | Promus Element | Bioabsorbable Polymer
      KOL-Index: 14765

      BACKGROUND: The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris.

      METHODS: We performed a randomized, double-blind trial to compare the two types of stents for revascularization of single, primary lesions in ...

      Known for Standard Stent | Coronary Revascularization | Randomized Comparison | Luminal Diameter | Rate Restenosis
      KOL-Index: 13516

      OBJECTIVES: This study sought to investigate whether self-expanding stents are more effective than balloon-expandable stents for reducing stent malapposition at 3 days after implantation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

      BACKGROUND: Acute myocardial infarction is associated with vasoconstriction and large thrombus burden. Resolution of vasoconstriction and thrombus load during the first hours to days after ...

      Known for Myocardial Infarction | Expandable Stents | Expanding Stent | Segment Elevation | Implantation Patients
      KOL-Index: 13367

      OBJECTIVES: In this substudy of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, we examined the longitudinal distribution of atherosclerotic plaque burden, virtual histology-intravascular ultrasound (VH-IVUS) characterized necrotic core (NC) content and VH-thin-cap fibroatheroma (TCFA) distribution in nonculprit lesions of patients presenting with acute coronary syndromes.

      BACKGROUND: Previous analyses suggested that vulnerable ...

      Known for Plaque Burden | Nonculprit Lesions | Acute Coronary Syndromes | Necrotic Core | Longitudinal Distribution
      KOL-Index: 12814

      Our study objective was to assess the incidence, predictors, and implications of access site complications related to transfemoral transcatheter aortic valve implantation (TAVI). We pooled the prospective TAVI databases of 5 experienced centers in Europe enrolling only transfemoral cases for this analysis. Access site complications were defined according to the Valve Academic Research Consortium end-point definitions. The global transfemoral TAVI database contained 986 patients. ...

      Known for Access Site Complications | Valve Implantation | Female Gender | Incidence Predictors | Transfemoral Transcatheter
      KOL-Index: 12727

      BACKGROUND: The multicentre, randomised Benestent-II study investigated a strategy of implantation of a heparin-coated Palmar-Schatz stent plus antiplatelet drugs compared with the use of balloon angioplasty in selected patients with stable or stabilised unstable angina, with one or more de-novo lesions, less than 18 mm long, in vessels of diameter 3 mm or more.

      METHODS: 827 patients were randomly assigned stent implantation (414 patients) or standard balloon angioplasty (413 patients). ...

      Known for Selected Patients | Unstable Angioplasty | 12 Months | Coronary Artery Disease | Coated Stents
      KOL-Index: 12483

      The evaluation for European Union market approval of coronary stents falls under the Medical Device Directive that was adopted in 1993. Specific requirements for the assessment of coronary stents are laid out in supplementary advisory documents. In response to a call by the European Commission to make recommendations for a revision of the advisory document on the evaluation of coronary stents (Appendix 1 of MEDDEV 2.7.1), the European Society of Cardiology (ESC) and the European ...

      Known for Task Force | Coronary Stents | European Society | Executive Summary | Cardiovascular Interventions
      KOL-Index: 12117

      OBJECTIVES: The study sought to investigate the relationship between post-procedural asymmetry, expansion, and eccentricity indices of metallic everolimus-eluting stent (EES) and bioresorbable vascular scaffold (BVS) and their respective impact on clinical events at 1-year follow-up.

      BACKGROUND: Mechanical properties of a fully BVS are inherently different from those of permanent metallic stent.

      METHODS: The ABSORB II (A bioresorbable everolimus-eluting scaffold versus a metallic ...

      Known for Eluting Scaffold | Bioresorbable Everolimus | Metallic Stent | Procedural Asymmetry | Absorb Trial
      KOL-Index: 12009

      OBJECTIVES: This study was designed to evaluate long-term clinical and economic outcomes for subjects receiving Endeavor drug-eluting versus Driver bare-metal stents (both Medtronic CardioVascular, Santa Rosa, California).

      BACKGROUND: Early studies found that the drug-eluting stent (DES) was a clinically and economically attractive alternative to the bare-metal stent; however, associations between DES and very late stent thrombosis suggest that longer follow-up is required.

      METHODS: We ...

      Known for Eluting Stent | Difference 95 | Economic Analysis | Randomized Controlled | Term Clinical
      KOL-Index: 11848

      OBJECTIVES: The purpose of this study is to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting stents (SES) in the ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery bypass graft (CABG) and bare-metal stenting (BMS) from the ARTS I.

      BACKGROUND: The long-term outcomes after SES implantation in patients with multivessel disease remains to be established.

      METHODS: The ARTS I was a randomized trial of 1,205 patients with ...

      Known for Eluting Stent | Cabg Bms | Coronary Artery | Multivessel Disease | 5 Years
      KOL-Index: 11547

      OBJECTIVES: This study sought to determine the mechanistic effects of a novel balloon-based lithoplasty system on heavily calcified coronary lesions and subsequent stent placement using optical coherence tomography (OCT).

      BACKGROUND: The Shockwave Coronary Rx Lithoplasty System (Shockwave Medical, Fremont, California) delivers localized, lithotripsy-enhanced disruption of calcium within the target lesion (i.e., lithoplasty) for vessel preparation before stent implantation.

      METHODS: We ...

      Known for Coronary Lithoplasty | Calcified Lesions | Optical Coherence | Stent Implantation | Angioplasty Balloon

      Key People For Aortic Valve

      Top KOLs in the world
      #1
      Martin B Leon
      aortic valve intravascular ultrasound coronary artery
      #2
      John G Webb
      aortic valve cardiogenic shock 1 year
      #3
      Michael J Mack
      aortic valve coronary artery united states
      #4
      David Craig Miller
      aortic valve mitral regurgitation marfan syndrome
      #5
      Lars Georg Svensson
      aortic valve partner trial united states
      #6
      CATHERINE M OTTO
      aortic stenosis valvular heart disease mitral regurgitation

      Clinique Pasteur, Toulouse, France | Clinique Pasteur, Toulouse, France. | Clinique Pasteur, 31000 Toulouse, France;, fajadet@interv-cardio-toul.com | Département de Cardiologie, Clinique Pasteur, Toulouse, France | Clinique Pasteur, Toulouse, France

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.